Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements Of Operations

v2.4.0.6
Condensed Consolidated Statements Of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Revenues:        
Royalties $ 2,431 $ 1,774 $ 6,597 $ 5,337
Material sales 1,679   5,713  
Collaborative research and development and other revenues 1,631 6,028 4,791 14,261
Total revenues 5,741 7,802 17,101 19,598
Operating costs and expenses:        
Cost of sales 703   2,851  
Research and development 2,471 4,935 7,693 18,912
General and administrative 3,962 3,074 11,261 9,363
Write-off of in-process research and development 2,282   2,282  
Lease exit and termination costs (2) 15,894 (168) 15,942
Total operating costs and expenses 9,416 23,903 23,919 44,217
Accretion of deferred gain on sale leaseback 426 426 1,277 1,277
Loss from operations (3,249) (15,675) (5,541) (23,342)
Other income (expense):        
Interest income 1 59 31 387
Interest expense (700) (8) (1,793) (39)
Decrease (increase) in liability for contingent value rights 224 2,460 (835) 6,702
Other, net (10) 1,728 74 2,476
Total other income (expense), net (485) 4,239 (2,523) 9,526
Income (loss) before income taxes (3,734) (11,436) (8,064) (13,816)
Income tax expense (benefit) (22) (419) 13,427 (1,318)
Income (loss) from continuing operations (3,756) (11,855) 5,363 (15,134)
Discontinued operations:        
Discontinued operations   12 3 258
Net income (loss): (3,756) (11,843) 5,366 (14,876)
Basic and diluted per share amounts:        
Income (loss) from continuing operations $ (0.19) $ (0.60) $ 0.27 $ (0.77)
Discontinued operations       $ 0.01
Net income (loss) $ (0.19) $ (0.60) $ 0.27 $ (0.76)
Weighted average number of common shares - basic 19,673,160 19,629,693 19,648,947 19,607,087
Weighted average number of common shares - diluted 19,673,160 19,629,693 19,686,353 19,607,087
AVINZA Product Line [Member]
       
Discontinued operations:        
Gain on sale of a product line   11   23
Oncology Product Line [Member]
       
Discontinued operations:        
Gain on sale of a product line   $ 1 $ 3 $ 235